Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 8/20 | 0.53 |
| ▸ | CDK2 | P24941 | 8/20 | 0.53 |
| ▸ | EIF2AK2 | P19525 | 6/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413076 | 0.85 | CDK4 (0.48) | CDK4CDK2EIF2AK2 | |
| SCHEMBL4413081 | 0.85 | CDK4 (0.48) | CDK4CDK2EIF2AK2 | |
| SCHEMBL4424686 | 0.85 | CDK4 (0.48) | CDK4CDK2EIF2AK2MAPK8 | |
| SCHEMBL8318732 | 0.75 | MAPK1 (0.52) | CDK4CDK2EIF2AK2 | |
| SCHEMBL14011246 | 0.75 | MAPK1 (0.45) | CDK4CDK2EIF2AK2IDH1 | |
| SCHEMBL4425029 | 0.74 | EIF2AK2 (0.46) | CDK4CDK2EIF2AK2 | |
| SCHEMBL4425032 | 0.74 | EIF2AK2 (0.46) | CDK4CDK2EIF2AK2 | |
| SCHEMBL8317782 | 0.72 | EIF2AK2 (0.45) | CDK4CDK2EIF2AK2 | |
| SCHEMBL8325329 | 0.71 | CDK4 (0.50) | CDK4CDK2EIF2AK2MAPK9 | |
| SCHEMBL8316804 | 0.70 | CDK4 (0.59) | CDK4CDK2EIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606284-B1 | COMPOSITIONS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7456190-B2 | Compositions useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456190-B2 | Compositions useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456190-B2 | Compositions useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1606284-A1 | COMPOSITIONS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040220200-A1 | Compositions useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-04 | — | — | US | disclosed |
| WO-2004083203-A1 | COMPOSITIONS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220200-A1 | Compositions useful as protein kinase inhibitors | PRKCH, MAP3K20, PACSIN2 | CDK4 380/4885CDK2 106/4885EIF2AK2 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.